Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

98.54USD
10:05am EST
Change (% chg)

$-0.46 (-0.46%)
Prev Close
$99.00
Open
$98.71
Day's High
$99.23
Day's Low
$98.35
Volume
34,200
Avg. Vol
551,924
52-wk High
$153.14
52-wk Low
$96.64

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $20,892.69
Shares Outstanding(Mil.): 211.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia

* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia

Nov 15 2017

BRIEF-Incyte says Q3 earnings per share $0.17

* Incyte reports 2017 third-quarter financial results and updates on key clinical programs

Oct 31 2017

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

Oct 31 2017

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON, Oct 31 AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

Oct 31 2017

BRIEF-Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer

* Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer

Oct 31 2017

BRIEF-Incyte Corp names new member to its board of directors

* Incyte names new member to its board of directors Source text for Eikon: Further company coverage:

Oct 30 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

Oct 25 2017

BRIEF-Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent

* Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​ Source text for Eikon: Further company coverage:

Oct 19 2017

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 25 2017

CORRECTED-UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 25 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.51 +0.09
Abbott Laboratories (ABT.N) $56.13 +0.33
Amgen, Inc. (AMGN.OQ) $170.12 +0.16
Biogen Inc (BIIB.OQ) $308.97 -0.83
Roche Holding Ltd. (ROG.S) CHF246.90 --
Roche Holding Ltd. (RO.S) CHF248.20 --
Sanofi SA (SASY.PA) €77.54 --

Earnings vs. Estimates